<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282839</url>
  </required_header>
  <id_info>
    <org_study_id>TCVGH-1047004C</org_study_id>
    <nct_id>NCT02282839</nct_id>
  </id_info>
  <brief_title>Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation</brief_title>
  <official_title>The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll 60 consecutive patients who are scheduled to receive radiotherapy
      with/without chemotherapy due to head and neck cancers. Basic data will be recorded along
      with tumor related variables. Then they will be divided randomly into study group and control
      group. The study group will receive oral glutamine during radiotherapy while the control
      group will receive placebo during radiotherapy. The severity of oral mucositis (WHO grading
      system), pain status (visual analogue scale), quality of life questionnaires will also be
      documented. The differences between the two groups will be analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy and radiotherapy are important therapeutic modalities for head and neck cancer
      patients. Oral mucositis is a common comorbidity during chemotherapy and radiotherapy. It was
      reported that 30-60% of patients underwent chemotherapy and over 90% of patients receiving
      radiotherapy had oral mucositis. Oral mucositis not only reduces the quality of life of
      cancer patients during therapy but also causes dysphagia and poor nutritional status. Severe
      oral mucositis may necessitate unplanned gaps between treatment which can undermine the
      chance of local control.

      In terms of management of oral mucositis, maintaining of oral hygiene and avoid infection are
      essential manner. Topical agents such as sucralfate, benzydamine, antifungal drugs, vitamin E
      and treatment using laser were studied in the management of oral mucositis. Previous studies
      indicated the glutamine significantly reduced the incidence and severity of oral mucositis in
      patients underwent chemotherapy and bone marrow transplantation. However, few studies
      discussed the effect of glutamine on the impact of oral mucositis in head and neck cancer
      patients receiving radiotherapy with/without chemotherapy.

      This study will enroll 60 consecutive patients who are scheduled to receive radiotherapy
      with/without chemotherapy due to head and neck cancers. Basic data will be recorded along
      with tumor related variables. Then they will be divided randomly into study group and control
      group. The study group will receive oral glutamine while the control group will receive
      placebo during radiotherapy. The severity of oral mucositis (WHO grading system, every week),
      pain status (visual analogue scale, every week), quality of life questionnaires (before,
      during and after radiotherapy) will also be documented. The differences between the two
      groups will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral mucositis</measure>
    <time_frame>8 weeks</time_frame>
    <description>According to WHO grading system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain status</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pain status by visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Washington University Quality of life questionaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>Powder that soluble in water for drinking, 10g TID (total 30 g per day)</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>AMINOPURE (Ajinomoto AmoniScience LLC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Head and neck cancer patients scheduled to receive radiotherapy with or without
             chemotherapy

        Exclusion Criteria:

          -  Prior radiotherapy to the head and neck region

          -  Severe liver or renal disease

          -  Reye's syndrome

          -  Allergy to glutamine

          -  Reluctant to join the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Otolaryngology Head Neck Surgery, Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-An Liu, MD</last_name>
      <phone>+886-4-23592525</phone>
      <phone_ext>5401</phone_ext>
      <email>saliu@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap B, Lee L, Kaczmarski E, Slevin N. A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Br J Oral Maxillofac Surg. 2012 Apr;50(3):221-6. doi: 10.1016/j.bjoms.2011.03.005. Epub 2011 Jun 1.</citation>
    <PMID>21636188</PMID>
  </reference>
  <reference>
    <citation>Wu SX, Cui TT, Zhao C, Pan JJ, Xu BY, Tian Y, Cui NJ. A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2010 Oct;97(1):113-8. doi: 10.1016/j.radonc.2010.08.003. Epub 2010 Sep 7.</citation>
    <PMID>20826029</PMID>
  </reference>
  <reference>
    <citation>Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanicolaou VS, Kouvaris J. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer. 2006 Jan;14(1):44-51. Epub 2005 Jun 10.</citation>
    <PMID>15947956</PMID>
  </reference>
  <reference>
    <citation>Lin YS, Lin LC, Lin SW, Chang CP. Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study. Nutr Cancer. 2010;62(5):682-91. doi: 10.1080/01635581003605532.</citation>
    <PMID>20574929</PMID>
  </reference>
  <reference>
    <citation>Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl). 2009 Mar;18(2):174-8. doi: 10.1111/j.1365-2354.2008.00943.x.</citation>
    <PMID>19267733</PMID>
  </reference>
  <reference>
    <citation>Gautam AP, Fernandes DJ, Vidyasagar MS, Maiya AG, Nigudgi S. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy--a randomized controlled trial. Support Care Cancer. 2013 May;21(5):1421-8. doi: 10.1007/s00520-012-1684-4. Epub 2012 Dec 8.</citation>
    <PMID>23224689</PMID>
  </reference>
  <reference>
    <citation>Le QT, Kim HE, Schneider CJ, Murak√∂zy G, Skladowski K, Reinisch S, Chen Y, Hickey M, Mo M, Chen MG, Berger D, Lizambri R, Henke M. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011 Jul 10;29(20):2808-14. doi: 10.1200/JCO.2010.32.4095. Epub 2011 Jun 13.</citation>
    <PMID>21670453</PMID>
  </reference>
  <reference>
    <citation>Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, Ilha L. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck. 2004 Apr;26(4):313-21.</citation>
    <PMID>15054734</PMID>
  </reference>
  <reference>
    <citation>Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar ME, Roth B, Negretti G, Sheinker B, Uchima P. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1330-7. Epub 2006 Jun 9.</citation>
    <PMID>16765532</PMID>
  </reference>
  <reference>
    <citation>Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2007 Jan 15;109(2):322-31.</citation>
    <PMID>17154160</PMID>
  </reference>
  <reference>
    <citation>Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, Jackson GB, Sandler ES. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005 Oct;36(7):611-6.</citation>
    <PMID>16086046</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Veterans General Hospital</investigator_affiliation>
    <investigator_full_name>Shih-An Liu</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Oral mucositis</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

